Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00802100 · ClinicalTrials.gov registry record · Phase 4
Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia
A Phase 4 study of Schizophrenia, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
- 13
- Study locations
NCT00802100: Completed Phase 4 study of Schizophrenia, sponsored by National Institute of Mental Health (NIMH).
NCT00802100 is a Phase 4 study of Schizophrenia that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 21 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (90% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00802100, a Phase 4 study of Schizophrenia, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study will compare the safety and effectiveness of three different antipsychotic medications, as well as the use of other medications to limit treatment side effects, in adults with schizophrenia.
Primary Outcome
Goal was to randomize 60 participants who met eligibility criteria.
Conditions Studied
Interventions
- DRUG Metformin
- DRUG Olanzapine
- DRUG Simvastatin
- DRUG Aripiprazole
- DRUG Perphenazine
Study Locations (13)
California
- SHANTI Clinical Trials - Colton
- Stanford University - Palo Alto
Texas
- University of Texas Southwestern Medical Center - Dallas
- Baylor College of Medicine - Houston
Connecticut
- Yale University - New Haven
Florida
- University of Miami School of Medicine - Miami
Georgia
- Medical College of Georgia - Augusta
Maryland
- Clinical Insights - Glen Burnie
Massachusetts
- University of Massachusetts - Worcester
Michigan
- Wayne State University - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-10 |
| Phase | Phase 4 |
What the finished NCT00802100 record still lists
NCT00802100 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 5 interventions - of which Metformin is the first listed.
NCT00802100 lists 13 locations in 11 states (California, Texas, Connecticut).
Frequently Asked Questions
What is clinical trial NCT00802100 about?
NCT00802100 is a clinical study titled "Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia". This study will compare the safety and effectiveness of three different antipsychotic medications, as well as the use of other medications to limit treatment side effects, in adults with schizophrenia.
What is the current status of trial NCT00802100?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2008-12. Estimated completion is 2009-10.
What conditions does trial NCT00802100 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00802100?
The interventions under investigation include: Metformin (DRUG), Olanzapine (DRUG), Simvastatin (DRUG), Aripiprazole (DRUG), Perphenazine (DRUG).
Who is sponsoring clinical trial NCT00802100?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00802100 being conducted?
This trial has 13 study locations across California, Connecticut, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00802100's enrollment target sits among peer trials
21 282nd of 315 higher than 31 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia